Hanmi Pharmaceutical Company Limited
Clinical trials sponsored by Hanmi Pharmaceutical Company Limited, explained in plain language.
-
New obesity drug HM15275 shows promise in Mid-Stage trial
Disease control OngoingThis study tests a new drug called HM15275 to help people with obesity lose weight. It involves 267 adults who are obese or overweight but do not have diabetes. Participants receive either the drug or a placebo for 36 weeks to see how much weight they lose and if the drug is safe…
Phase: PHASE2 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Disease control
Last updated May 26, 2026 08:11 UTC
-
New weekly shot shows promise for rare Low-Blood-Sugar condition
Disease control OngoingThis study tests a new medicine called HM15136 for people aged 2 and older with congenital hyperinsulinism (CHI), a rare condition that causes dangerously low blood sugar. The medicine is given as a weekly shot alongside standard treatments. The goal is to see if it is safe and h…
Phase: PHASE2 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New drug shows promise against fatty liver disease in Mid-Stage trial
Disease control OngoingThis study tests a new drug, HM15211, for people with NASH, a serious fatty liver disease that can lead to scarring. About 215 adults with confirmed NASH and liver scarring will receive the drug or a placebo for 12 months. The main goal is to see if the drug can reduce liver infl…
Phase: PHASE2 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Disease control
Last updated May 19, 2026 11:47 UTC